Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson's Disease: A Pilot Study

IF 5 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2025-07-27 DOI:10.1111/cns.70541

Yitong Du, Lin Wang, Ying Cui, Xiaojiao Xu, Mingkai Zhang, Yue Li, Ting Gao, Dan Gao, Zhi Sheng, Shiya Wang, Houzhen Tuo

{"title":"Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson's Disease: A Pilot Study","authors":"Yitong Du, Lin Wang, Ying Cui, Xiaojiao Xu, Mingkai Zhang, Yue Li, Ting Gao, Dan Gao, Zhi Sheng, Shiya Wang, Houzhen Tuo","doi":"10.1111/cns.70541","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Parkinson's disease (PD) patients experience gut microbiota dysbiosis. Probiotic intervention could potentially serve as a safe and effective adjunctive therapeutic approach for PD, but its effects on rapid eye movement sleep behavior disorder (RBD) and motor symptoms in PD patients warrant further investigation.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To examine the influence of probiotics on RBD, motor symptoms, gut microbiota, and serum metabolites in individuals with PD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this randomized controlled trial, PD patients were randomly allocated to either a probiotics or a control group while maintaining standard treatments. Clinical outcomes, including Unified Parkinson's Disease Rating Scale (UPDRS) and RBD Questionnaire-Hong Kong (RBDQ-HK) were assessed at baseline and post-treatment. Furthermore, fecal and blood samples were collected from PD patients at both timepoints, with additional samples obtained from healthy controls for comparison. The 16S rRNA gene V3-V4 region sequencing method was used to analyze gut microbiota composition, and untargeted metabolomic techniques were utilized to assess serum metabolite alterations, followed by correlation analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty eligible PD patients were enrolled and randomly allocated into two groups. After 12 weeks of intervention, the probiotic group showed significant reductions in both UPDRS total scores (−4.8 ± 7.5 vs. 1.8 ± 13.1, <i>p</i> = 0.009) and RBDQ-HK scores (−7.5 ± 6.5 vs. 0 ± 5.8, <i>p</i> = 0.015) compared to controls. Gut microbiota analysis revealed increased abundance of <i>Actinobacteria</i>, <i>Negativicutes</i>, and <i>Bacillus</i>, with reductions in <i>Lactococcus</i>, <i>Comamonas</i>, and <i>Enterococcus</i> after probiotic intervention. Furthermore, compared to normal controls, PD patients exhibited 9 significantly elevated and 11 significantly reduced metabolites; probiotic intervention altered the serum metabolome in PD patients.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study demonstrated probiotics' potential to ameliorate RBD and motor symptoms while positively affecting the composition of the gut microbiota and serum metabolites in PD patients.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 7","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70541","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70541","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Parkinson's disease (PD) patients experience gut microbiota dysbiosis. Probiotic intervention could potentially serve as a safe and effective adjunctive therapeutic approach for PD, but its effects on rapid eye movement sleep behavior disorder (RBD) and motor symptoms in PD patients warrant further investigation.

Objectives

To examine the influence of probiotics on RBD, motor symptoms, gut microbiota, and serum metabolites in individuals with PD.

Methods

In this randomized controlled trial, PD patients were randomly allocated to either a probiotics or a control group while maintaining standard treatments. Clinical outcomes, including Unified Parkinson's Disease Rating Scale (UPDRS) and RBD Questionnaire-Hong Kong (RBDQ-HK) were assessed at baseline and post-treatment. Furthermore, fecal and blood samples were collected from PD patients at both timepoints, with additional samples obtained from healthy controls for comparison. The 16S rRNA gene V3-V4 region sequencing method was used to analyze gut microbiota composition, and untargeted metabolomic techniques were utilized to assess serum metabolite alterations, followed by correlation analysis.

Results

Fifty eligible PD patients were enrolled and randomly allocated into two groups. After 12 weeks of intervention, the probiotic group showed significant reductions in both UPDRS total scores (−4.8 ± 7.5 vs. 1.8 ± 13.1, p = 0.009) and RBDQ-HK scores (−7.5 ± 6.5 vs. 0 ± 5.8, p = 0.015) compared to controls. Gut microbiota analysis revealed increased abundance of Actinobacteria, Negativicutes, and Bacillus, with reductions in Lactococcus, Comamonas, and Enterococcus after probiotic intervention. Furthermore, compared to normal controls, PD patients exhibited 9 significantly elevated and 11 significantly reduced metabolites; probiotic intervention altered the serum metabolome in PD patients.

Conclusions

This study demonstrated probiotics' potential to ameliorate RBD and motor symptoms while positively affecting the composition of the gut microbiota and serum metabolites in PD patients.

Abstract Image

查看原文本刊更多论文

补充益生菌对帕金森病快速眼动睡眠行为障碍和运动症状的影响：一项初步研究

帕金森氏病（PD）患者会经历肠道菌群失调。益生菌干预可能是一种安全有效的PD辅助治疗方法，但其对PD患者快速眼动睡眠行为障碍（RBD）和运动症状的影响有待进一步研究。目的探讨益生菌对帕金森病患者RBD、运动症状、肠道菌群和血清代谢物的影响。方法在本随机对照试验中，PD患者在维持标准治疗的同时，随机分为益生菌组和对照组。临床结果包括统一帕金森病评定量表（UPDRS）和RBD问卷-香港（RBDQ-HK）在基线和治疗后进行评估。此外，在两个时间点收集PD患者的粪便和血液样本，并从健康对照中获取额外样本进行比较。采用16S rRNA基因V3-V4区测序法分析肠道菌群组成，采用非靶向代谢组学技术评估血清代谢物变化，并进行相关性分析。结果入选50例PD患者，随机分为两组。干预12周后，与对照组相比，益生菌组UPDRS总分（- 4.8±7.5比1.8±13.1,p = 0.009）和RBDQ-HK评分（- 7.5±6.5比0±5.8,p = 0.015）均显著降低。肠道菌群分析显示，在益生菌干预后，放线菌、阴性菌和芽孢杆菌的丰度增加，乳球菌、单胞菌和肠球菌的丰度减少。此外，与正常对照相比，PD患者的代谢物有9个显著升高，11个显著降低；益生菌干预改变了PD患者的血清代谢组。结论：本研究表明，益生菌具有改善RBD和运动症状的潜力，同时对PD患者的肠道微生物群组成和血清代谢物产生积极影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.